From blockbuster to “nichebuster”: how a flawed legislation helped create a new profit model for the drug industry

Authors analysed 2 decades of sales data and found companies have reaped billions of profit off back of orphan drug designations, noting European Commission is set to publish review suggesting most of these drugs would have been launched anyway without favourable monopoly rights.


British Medical Journal